• About us
• Contact

Advertisement

Organisation › Details

2invest (Group)

2Invest AG (2Invest) is an investment company listed on the Frankfurt market formed in 2020 from the restructuring of businesses of 4basebio AG. Our investment objective is primarily but not exclusively to identify and support emerging companies with both strong management teams and ground-breaking technologies in the biotechnology, life sciences and IT sectors. Our ambition is to enable those companies to reach new and meaningful value inflexion points. *

 

	Start	2020-01-01 restructured
	Today	Expedeon AG (FSE: EXNN, ISIN: DE000A2Y801, Prime Standard)
	Predecessor	Expedeon (Group)
	Industry	finance
	Industry 2	LIFE SCIENCES
	Region	Heidelberg
	Country	Germany
	Street	3 Ziegelhäuser Landstr.
	City	69120 Heidelberg
	Tel	+49-6221-64924-0
		Address record changed: 2021-10-30
Basic data	Employees	n. a.
		* Document for »About Section«: Leucid Bio. (10/21/21). "Press Release: Leucid Bio Raises £11.5M in Series A Financing to Develop Next Generation of Innovative Chimeric Antigen Receptor T cell (CAR-T) Therapies". London.
		Record changed: 2023-12-30

Advertisement

More documents for 2invest (Group)

• [1] Expedeon AG. (11/11/19). "Press Release: Expedeon AG Signs EUR 120 Million Deal with Abcam for the Sale of Its immunology and Proteomics Business". Heidelberg & Cambridge....
• [2] Expedeon AG. (8/6/19). "Press Release: Expedeon AG Signs Commercial Agreement with Sona Nanotech". Halifax, Heidelberg & Cambridge....
• [3] Sygnis AG. (10/24/17). "Press Release: Sygnis AG Announces the Launch of the Universal Lateral Flow Assay Kit and Associated Patent Filing". Madrid & Heidelberg....
• [4] Sygnis AG. (10/18/17). "Press Release: Sygnis AG Announces Completion of Relocation of Its Innova Biosciences Unit to Allow for Expansion". Madrid & Heidelberg....
• [5] Sygnis AG. (8/3/17). "Press Release: Sygnis AG Reports Financial Results for the Second Quarter and First Six Months of 2017". Madrid & Heidelberg....
• [6] Sygnis AG. (5/8/17). "Press Release: Sygnis AG Plans to Acquire Profitable Innova Biosciences Ltd. for EUR 8 Million in Cash and up to 3.5 Million Shares [Not for USA, Canada, Japan and Australia]". Madrid & Heidelberg....
• [7] Sygnis AG. (4/27/17). "Press Release: Sygnis AG Reports Financial Results for Fiscal Year 2016". Madrid & Heidelberg....
• [8] Sygnis AG. (4/24/17). "Press Release: Sygnis AG Expands Access to Chinese Market with Second OEM Deal with Tanon". Madrid & Heidelberg....
• [9] Sygnis AG. (4/11/17). "Press Release: Sygnis AG Successfully Completes Integration of Recently Acquired C.B.S. Scientific". Madrid & Heidelberg....
• [10] Sygnis AG. (3/1/17). "Press Release: Sygnis AG Announces Management Changes. David Roth Appointed Chief Financial Officer (CFO) ". Madrid & Heidelberg....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.